ZYBERNO
Stock Report
Updated Sep 1, 2026

Alzamend Neuro, Inc. (ALZN)

Healthcare • NASDAQ

$1.66

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
2.0/100
POOR BUSINESS
Alzamend Neuro, Inc. (ALZN) scores 2/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-277.7%)
Debt-to-Equity (Solvency Risk):POOR (1.84x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-480.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Alzamend Neuro, Inc. (ALZN) stock report — Zyberno Score 2/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.66
Market Cap:$5.54M

Valuation Multiples (2)

P/B Ratio:7.56x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$6.18M

Price Action & Momentum (3)

Momentum Percentile:6 / 100
% of 52-Week High:61.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-200.1%
Reinvestment Rate:1.7%
Fundamental Growth Rate (g):-8.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$169.68
Dividend Yield:2.3%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.31x
Quick Ratio:1.31x
Cash Ratio:0.53x

Leverage Analysis (3)

Debt To Equity Ttm:1.84x
Debt-to-Equity Ratio:1.84x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,324.50x
Times Interest Earned:-1,324.50

Capital Structure (4)

Working Capital:418,345.00
Cash And Cash Equivalents:710,689.00
Long Term Debt:$0.00
Net Debt:$635.46K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$8.77M

Bottom Line Performance (3)

-$8.77M
Income Before Tax:-$8.77M
Ebitda Ttm:-8,656,101.00

Operating Expenses (5)

Operating Expenses:8,766,841.00
R And D Expense:3,629,785.00
Sga Expense:5,137,056.00
Income Tax Expense:$1.10K
Interest Expense:6,619.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$2.08M
Current Assets:$1.76M
Ppe Net:314,866.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,346,152.00
Current Liabilities:1,346,152.00
Long Term Debt:$0.00
Short Term Debt:$1.35M

Equity & Capital (3)

Equity:$733.21K
Retained Earnings:-$67.31M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,346,152.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:623,811.00
C. Cash Flow Analysis

Operating Activities (2)

-$8.07M$0.00

Investment Activities (1)

Investing Cash Flow:-$210.00K

Financing Activities (3)

Financing Cash Flow:$794.84K
Dividends Paid Ttm:117,022.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,000,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:110,740.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.63
-$2.63
Earnings Per Share Ttm:-$2.63

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.42

Book Value & Capital (2)

Book Value Per Share:$0.22
Cash Per Share:0.21

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.7%
Fundamental Growth Rate (g):-8.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-35.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ALZN
Company Name:Alzamend Neuro, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.34M
Shares Outstanding Basic:3.34M
Shares Outstanding Diluted:3.34M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 19:26:47 UTC
Data Timestamp:2026-08-22T06:46:09.252124
Scroll to Top